Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,020 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study.
Yan D, Niu S, Hu D, Dong W, Sun Y, Wang Q, Wang S, Gu Q, Liu G, Wang J, Chen L, Lv J, Zheng Q, Song H, Fang Y. Yan D, et al. Among authors: dong w. Expert Opin Investig Drugs. 2023 Feb;32(2):161-170. doi: 10.1080/13543784.2023.2178894. Epub 2023 Feb 20. Expert Opin Investig Drugs. 2023. PMID: 36755413 Clinical Trial.
A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults.
Wang J, Niu S, Dong W, Wei L, Ou L, Zhang T, Zhang L, Nie X, Wang Q, Shen T, Wang Q, Xia L, Liu G, Jin J, Zheng Q, Song H, Fang Y. Wang J, et al. Among authors: dong w. Expert Opin Investig Drugs. 2020 Jul;29(7):755-762. doi: 10.1080/13543784.2020.1770226. Epub 2020 Jun 27. Expert Opin Investig Drugs. 2020. PMID: 32594779 Clinical Trial.
Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C, Dong W, Xia L, Lv J, Jiang D, Wang Q, Wang M, Wu M, Miao J, Tao T, Wang D, Zheng L, Su S, Liu L, Fang Y. Liu C, et al. Among authors: dong w. Int Immunopharmacol. 2021 Feb;91:107263. doi: 10.1016/j.intimp.2020.107263. Epub 2020 Dec 28. Int Immunopharmacol. 2021. PMID: 33383447 Clinical Trial.
Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
Dong W, Chen M, Niu S, Wang B, Xia L, Wang J, Shen T, Wang Q, Lv J, Liu G, Fan H, Xie Z, Xie F, An Y, Zheng Q, Rao H, Song H, Fang Y. Dong W, et al. Expert Opin Biol Ther. 2022 Feb;22(2):253-262. doi: 10.1080/14712598.2021.1954157. Epub 2021 Jul 26. Expert Opin Biol Ther. 2022. PMID: 34236011 Clinical Trial.
8,020 results